<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): July 5, 2000
WATSON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C> <C>
Nevada 0-20045 95-3872914
(State of jurisdiction) (Commission File No.) (IRS Employer Identification No.)
</TABLE>
311 Bonnie Circle
Corona, California 92880
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (909) 270-1400
<PAGE> 2
Item 5. Other Events
On July 5, 2000, Watson Pharmaceuticals, Inc. (the "Company") announced the
expiration of a tender offer to acquire all of the outstanding shares of Schein
Pharmaceutical, Inc. ("Schein").
On July 6, 2000, the Company announced that it has accepted, or expects to
accept, 26,070,950 shares of common stock of Schein, equaling approximately
77.9% of the total outstanding shares of Schein. The Company announced further
that it paid for 24,565,962 shares of Schein common stock and that Notices of
Guaranteed Delivery were received for an additional 1,504,988 shares of Schein
common stock. The Company expects to pay for such shares after timely receipt of
proper documentation.
The Company's press releases, dated July 5, 2000, titled "Watson
Pharmaceuticals, Inc. Announces Expiration of Its Tender Offer for Schein
Pharmaceutical, Inc." and dated July 6, 2000, titled "Watson Pharmaceuticals,
Inc. Announces Completion of Tender Offer for Schein Pharmaceutical, Inc." are
attached hereto as Exhibits 99.1 and 99.2, respectively.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
(c) Exhibits
<TABLE>
<CAPTION>
Exhibit
Number Description
------- -----------
<S> <C>
99.1 Press Release dated July 5, 2000, titled, "Watson Pharmaceuticals, Inc.
Announces Expiration of Its Tender Offer for Schein Pharmaceutical, Inc."
99.2 Press Release dated July 6, 2000, titled, "Watson Pharmaceuticals, Inc.
Announces Completion of Tender Offer for Schein Pharmaceutical, Inc."
</TABLE>
2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
WATSON PHARMACEUTICALS, INC.
Dated: July 7, 2000 /s/ Robert C. Funsten
---------------------
Robert C. Funsten
Senior Vice President,
General Counsel and Secretary
3
<PAGE> 4
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit
Number Description
------- -----------
<S> <C>
99.1 Press Release dated July 5, 2000, titled, "Watson Pharmaceuticals, Inc.
Announces Expiration of Its Tender Offer for Schein Pharmaceutical, Inc."
99.2 Press Release dated July 6, 2000, titled, "Watson Pharmaceuticals, Inc.
Announces Completion of Tender Offer for Schein Pharmaceutical, Inc."
</TABLE>
4
